Krystal Corp - KRYS Net earnings per share for the last four quarters

Krystal Biotech Corp. (KRYS) - corporate logo

Krystal Biotech, Inc. (KRYS) combines in-house production with external testing, although the high cost of therapy creates financial risks. On GURU.Markets, the rolling year YoY EPS growth chart visualizes these factors, where 11.40 represents the latest level value. Patent protection for unique gene delivery methods and strict FDA regulatory requirements guarantee business stability.

KRYS: Krystal Biotech, Inc. Earnings per share for the last twelve months 02/11/2024 - 11/17/2026

Financial and market metric breakdowns for Krystal Biotech Inc (KRYS)

- current quotes and average value forecast:
Initial company analysis:KRYS (Krystal Corp)
Product sample of Krystal Biotech

This indicator measures the dynamics of net earnings per share over the last twelve months relative to the same period last year, reflecting the scaling rate of the business's actual earnings. By analyzing the current EPS YoY TTM growth rate, an investor can see the results of the commercialization of gene therapy and the R&D pipeline efficiency of Krystal Biotech, Inc. (KRYS) during the implementation of innovative treatments for skin and lung diseases.